Indian Natco marketed Glivec's copy product

Published: 2003-02-04 07:00:00

Updated: 2003-02-04 07:00:00

An Indian pharmaceutical maker Natco marketed on January 26 Veenat (imatinib mesylate), an identical substance to Glivec through the market approval from the Indian government. Any pharmaceutical makers can produce copy products like Glivec due to the fact that India has not introduced a product ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK